Form 4: Oncology Institute Director Increases Stake Through Warrant Exercise

A director of The Oncology Institute, Inc. exercised warrants, resulting in a net increase in their indirect beneficial ownership of common stock.

Summary

• Richard A. Barasch, a director of The Oncology Institute, Inc. (TOI), engaged in a cashless exercise of a Common Stock Purchase Warrant on June 17, 2025.
• RAB Ventures (DFP) LLC, an entity controlled by Mr. Barasch, exercised warrants to acquire 679,224 shares of common stock at an exercise price of $1.198 per share.
• In connection with this cashless exercise, 311,128 shares were withheld by the Issuer for payment of the exercise price, valued at $2.6154 per share.
• The fair market value of $2.6154 per share was determined based on the average volume-weighted average price (VWAP) over the five consecutive trading days immediately prior to the exercise date.
• This resulted in a net acquisition of 368,096 shares (679,224 acquired 311,128 withheld) by RAB Ventures (DFP) LLC.
• Following these transactions, RAB Ventures (DFP) LLC's indirect beneficial ownership of The Oncology Institute, Inc. common stock stands at 2,923,637 shares.
• The Issuer and RAB Ventures (DFP) LLC entered into a Waiver Agreement to permit the cashless exercise, waiving a provision that restricted such exercises if underlying shares were not covered by an effective registration statement.
• The exercise of the Common Warrant is exempt pursuant to Rule 16b-6 of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The net increase in a director's indirect beneficial ownership through a warrant exercise is generally viewed positively, indicating insider confidence. While the cashless exercise and waiver introduce some complexity, the overall outcome is an increased stake by a key insider.

Positives

• A director, through an affiliated entity, increased their net beneficial ownership of the company's common stock by 368,096 shares, which can signal confidence in the company's future prospects.
• The exercise price of the warrant ($1.198) was significantly lower than the fair market value of the common stock ($2.6154) at the time of exercise, indicating the warrant was 'in the money' and the transaction was financially beneficial for the reporting person.

Negatives

• The cashless exercise mechanism involved withholding a substantial number of shares (311,128) to cover the exercise price, rather than a direct cash payment.
• A Waiver Agreement was required to facilitate the cashless exercise, indicating a deviation from standard warrant terms regarding the registration status of the underlying shares.

Risks

• The necessity of a Waiver Agreement suggests potential issues or complexities with the registration statement covering the underlying shares, which could impact future liquidity or the ability of the warrant holder to sell these shares without further action.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook. It only indicates the expiration date of the exercised warrant.

Management Comments

• "The reporting person disclaims beneficial ownership of these securities except to the extent of the reporting person's pecuniary interest therein."

Industry Context

This document details an insider stock transaction within the healthcare sector, specifically for a company focused on oncology. While the transaction itself is a routine financial event for insiders, a director increasing their stake could be interpreted as a positive signal regarding the company's prospects within the competitive oncology services market.

Comparison to Industry Standards

• This document reports a specific insider transaction (warrant exercise and cashless exercise) and does not provide company-wide financial or operational results that can be directly compared to industry standards or competitors. The mechanisms of warrant exercise and cashless exercise are standard financial practices.

Corporate Governance

Related Party Transactions

• RAB Ventures (DFP) LLC, an entity controlled by reporting person Richard A. Barasch (a director of The Oncology Institute, Inc.), engaged in transactions with The Oncology Institute, Inc. involving the exercise of a Common Warrant.
• The Issuer and RAB Ventures (DFP) LLC entered into a Waiver Agreement related to the cashless exercise of the warrant.

Stakeholder Impact

• Shareholders: The net increase in a director's indirect ownership could be perceived positively, signaling confidence in the company's future. The specific mechanics of the cashless exercise and the waiver are particular to this transaction and do not directly impact other shareholders' holdings, but the waiver might indicate a specific situation regarding share registration.

Next Steps

• The Common Warrant, which was partially exercised, has an expiration date of March 26, 2030, indicating potential for future exercise or expiry of any remaining unexercised portions.

Key Dates

Keywords

The Oncology Institute, TOI, SEC Form 4, Insider Trading, Beneficial Ownership, Warrant Exercise, Cashless Exercise, Director Stock Ownership, Healthcare, Oncology